Who Paid My Doc
Stephen Gottlieb
Cardiovascular Disease Baltimore, MD Medical Doctor
NPI 1306808894 CMS profile 13978
22 S Greene St, Baltimore, MD 21201
General payments
$43,542
Research payments
$3,200
Ownership & investment interest
$0
Research they led as principal investigator
$1,313,699
Through program year 2025, Stephen Gottlieb of Baltimore, MD is reported in the CMS Open Payments database as having received $43,542 across 28 general payments and $3,200 in research payments paid to them. Separately, studies naming them as principal investigator received $1,313,699 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $20 | 1 | |
| 2024 | General | $800 | 1 | |
| 2023 | General | $3,327 | 5 | |
| 2022 | General | $8,136 | 8 | |
| 2021 | General | $9,000 | 4 | |
| 2020 | General | $13,775 | 2 | |
| 2020 | Research | $3,200 | 1 | |
| 2019 | General | $8,483 | 7 |
Beside peers
- Stephen Gottlieb
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Stephen Gottlieb were reported at $20. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Stephen Gottlieb | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,483 | $450 | $127–$1,392 | $163 |
| 2020 | $13,775 | $242 | $77–$751 | $114 |
| 2021 | $9,000 | $335 | $101–$1,037 | $132 |
| 2022 | $8,136 | $395 | $121–$1,211 | $149 |
| 2023 | $3,327 | $443 | $136–$1,283 | $160 |
| 2024 | $800 | $450 | $136–$1,323 | $164 |
| 2025 | $20 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
755
Drug cost
$4,016,104
Branded share of claims
43.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Vyndamax Tafamidis | Brand | 155 | $3,789,651 | |
| Entresto Sacubitril/Valsartan | Brand | 59 | $87,996 | |
| Jardiance Empagliflozin | Brand | 36 | $43,161 | |
| Farxiga Dapagliflozin Propanediol | Brand | 33 | $37,023 | |
| Eliquis Apixaban | Brand | 26 | $32,317 | |
| Xarelto Rivaroxaban | Brand | 19 | $16,235 | |
| Eplerenone | Generic | 38 | $3,908 | |
| Metoprolol Succinate | Generic | 68 | $1,690 | |
| Torsemide | Generic | 20 | $870 | |
| Atorvastatin Calcium | Generic | 68 | $761 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 16 billing codesPaid by Medicare
$38,570
Medicare patients
232
Services billed
548
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 71% | |
| Ischemic heart disease | 58% | |
| Chronic kidney disease | 50% | |
| Diabetes | 49% | |
| Atrial fibrillation | 44% | |
| Arthritis | 44% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
29 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Maryland
Navin Kapur
Cardiovascular Disease · Baltimore, MD
Michael Blaha
Cardiovascular Disease · Baltimore, MD
Sanjay Rajagopalan
Cardiovascular Disease · Baltimore, MD
Allen Taylor
Cardiovascular Disease · N Bethesda, MD
David Gooray
Cardiovascular Disease · Largo, MD
Erin Michos
Cardiovascular Disease · Baltimore, MD
Related records
Cardiovascular Disease in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.